跳至主要内容
临床试验/EUCTR2013-003144-23-GB
EUCTR2013-003144-23-GB进行中(未招募)1 期

Pregnancy And chronic hypertension: NifeDipine or labetalol as Antihypertensive treatment - PANDA

King's College London0 个研究点开始时间: 2013年10月30日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
Female

入选标准

  • Chronic hypertension (defined as diastolic blood pressure (BP) >=90mmHg present at booking or before 20 weeks' gestation, or requiring treatment outside pregnancy and/or at time of referral)
  • Gestation 12-28 weeks’ gestation
  • Singleton pregnancy
  • Able to provide informed consent
  • Age >=18 years
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 114
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Contraindication to labetalol (including asthma, uncontrolled heart failure, Prinzmetal's angina, marked bradycardia, hypotension, sick sinus syndrome, second- or third- degree AV block, cardiogenic shock, metabolic acidosis, severe peripheral arterial disease; phaeochromocytoma) or nifedipine (including cardiogenic shock; advanced aortic stenosis; within 1 month of myocardial infarction; unstable or acute attacks of angina)
  • Insufficient understanding of the trial

研究者

相似试验